Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELCOVID Study: Phase II Trial of Intravenous Melatonin in ICU Patients with COVID-19
2020-001808-42Phase 2Completed
- Sponsor
- Pharmamel
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing Intravenous melatonin with Placebo (2 arms). Primary endpoint: Mortality. Started Jul 2020; status: completed.
02
Drugs
melatonin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001808-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001808-42.